Important note: Information in this article was accurate in October 2001. The state of the art may have changed since the publication date.AIDSWEEKLY Plus; Monday, October 22 & 29, 2001
Staff Medical Writers
NewsRx -- In heterosexual couples where one partner is HIV positive, viral load, or the amount of detectable virus in the blood, is a much stronger predictor of the risk of transmission in women than in men, according to a study by researchers at the University of Alabama at Birmingham (UAB).
Details of the study were published in the journal AIDS Research and Human Retroviruses1.
"Although we've known that high viral loads are associated with a person's risk of transmission, it appears that women with high viral loads are much more contagious than men with high viral loads," says Dr. Susan Allen, associate professor of epidemiology and international health with the School of Public Health at UAB. In the United States, heterosexual transmissions of HIV represent a rapidly increasing number of new infections. And in sub-Saharan Africa, where the study was conducted, heterosexual transmission is the primary means by which the virus is spread.
The study followed 1022 heterosexual couples for periods of two to 67 months over the course of six years. Couples enrolled in the Zambia-UAB HIV Research Project in Lusaka, Zambia, received counseling, free condoms and primary health care. In 162 couples, the infected partner transmitted the disease to the initially uninfected partner.
On average, those who transmitted the disease had significantly higher levels of virus in the blood than those who did not transmit the disease. However, women who transmitted the disease had four times the viral load of those who did not, while men who transmitted the disease had only one-and-a-half times the viral load of those who did not. These findings may have important implications for the role of HIV therapies and vaccines in reducing viral loads and the spread of the disease.
"The study indicates that therapies to lower viral loads could have a significant impact on reducing the risk of transmission, particularly from women to men," says Allen. "However, the majority of the world's HIV infections are in the poorest countries where therapies are not available. The development of a vaccine is urgently needed to stem the HIV pandemic."
The lead investigator of the study was Ulgen Semaye Fideli, MSPH, with the department of epidemiology and international health at UAB. In addition to Allen, other researchers who collaborated on the study are: Rosemary Musonda, PhD, with the Tropical Disease Research Center in Ndola, Zambia; Stan Trask, Beatrice Hahn, MD, and Heidi Weiss, PhD, with the division of hematology and oncology at UAB; Joseph Mulenga, MD, with the Zambia National Blood Transfusion Service; Francis Kasolo, PhD, with the Virology and Immunology Laboratory at University Teaching Hospital in Zambia; Sten Vermund, PhD, with the department of epidemiology and international health at UAB; and Grace Aldrovandi, MD, with the department of pediatrics at UAB.
This article was prepared by AIDS Weekly editors from staff and other reports.
Reference
1. Fideli US, Allen SA, Musonda R, Trask S, Hahn BH, Weiss H, Mulenga J, Kasolo F, Vermund SH, Aldrovandi GM, "Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa", AIDS Res Hum Retroviruses 2001 Jul 1;17(10):901-10
011022
AW011008
Copyright © 2001 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1990,2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.